Breaking News Instant updates and real-time market news.

DDAIF

Daimler AG

$0.00

(0.00%)

, FCAU

Fiat Chrysler

$19.33

-0.195 (-1.00%)

07:58
07/21/18
07/21
07:58
07/21/18
07:58

Week in review: How Trump's policies moved stocks

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Trump and his administration with this weekly recap compiled by The Fly: 1. AUTO-TRADE DEAL: President Donald Trump said there will be "tremendous retribution" if his meeting with EU officials next week does not result in what he views as a fair auto-trade deal, the Wall Street Journal reported on Wednesday. European Commission President Jean-Claude Juncker plans to visit the White House next Wednesday to "discuss a wide range of priorities, including foreign and security policy, counterterrorism, energy security, and economic growth," the report noted. Meanwhile, the publication also said that the U.S. auto complex, including manufacturers, parts suppliers and dealers are aligned in a "push back" against the Trump administration's proposal to apply tariffs on vehicles and components imported into the U.S., contending the administration's trade policy "will backfire and lead to higher prices and lost jobs." On Thursday, Reuters reported that the EU is readying a list of counter-measures to potential U.S. tariffs on European vehicles. Publicly traded companies in the space include Daimler AG (DDAIF), Fiat Chrysler (FCAU), Ford (F), General Motors (GM), Honda (HMC), Nissan (NSANY), Toyota (TM) and Volkswagen (VLKAY). 2. GOOGLE: President Trump tweeted on Thursday, "I told you so! The European Union just slapped a Five Billion Dollar fine on one of our great companies, Google [GOOG; GOOGL]. They truly have taken advantage of the U.S., but not for long!" 3. DRUG PRICES: President Donald Trump tweeted on Thursday, "Thank you to Novartis [NVS] for not increasing your prices on prescription drugs. Likewise to Pfizer [PFE]. We are making a big push to actually reduce the prices, maybe substantially, on prescription drugs." Later on Thursday, Merck (MRK) announced that it is committing to not increase the average net price across its portfolio of products by more than inflation annually and lowering its price on ZEPATIER by 60% and several other medicines by 10% to reduce out-of-pocket costs for U.S. patients. On Friday, Roche (RHHBY) told Dow Jones Newswires that it will not be taking any U.S. price increases for the remainder of the year. Sanofi (SNY) and Merck KGaA (MRK) also told Dow Jones they would either commit to their pricing strategies, or that they didn't have plans to raise prices in the U.S. 4. BOEING: On Wednesday, the White House Press Secretary issued a statement on the Air Force's award of a firm fixed price contract to Boeing (BA) to design, modify, test, certify, and deliver two Presidential, mission-ready aircraft by 2024. "The contract sets the total price for the two completed 'Air Force One' replacement aircraft at $3.9B, saving the taxpayers over $1.4B from the initially proposed $5.3B cost-plus contract. President Donald J. Trump has emphasized the need to minimize the cost of replacing the two existing Air Force One aircraft. Yesterday's action meets that objective and reflects the President's commitment to our military and to protecting taxpayer dollars," according to the White House's statement. 5. FOREIGN INVESTMENT: Congress is set to enact the first major changes in a decade to the U.S.'s process for vetting foreign investment, the Wall Street Journal reported on Thursday. Negotiators from the Senate and House reached an agreement on the final words of a provision to bolster both the Committee on Foreign Investment in the U.S. and the U.S. export control system to block Chinese and other foreign transactions that could negatively affect national security, the report says, citing Senate Majority Whip John Cornyn. "It's a done deal," Cornyn said in an interview. The measure, which has been attached to a defense spending bill, could be signed into law as soon as this month, the report noted. "Week in Review" is The Fly's weekly recap of its recurring series of "Trump Effect" exclusive stories.

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$19.33

-0.195 (-1.00%)

F

Ford

$10.56

-0.115 (-1.08%)

GM

General Motors

$39.39

0.08 (0.20%)

HMC

Honda

$29.18

-0.19 (-0.65%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$131.87

0.11 (0.08%)

VLKAY

Volkswagen

$0.00

(0.00%)

GOOG

Alphabet

$1,184.77

-2.37 (-0.20%)

GOOGL

Alphabet Class A

$1,198.05

-1.21 (-0.10%)

PFE

Pfizer

$37.33

-0.03 (-0.08%)

NVS

Novartis

$82.28

1.47 (1.82%)

RHHBY

Roche

$0.00

(0.00%)

SNY

Sanofi

$42.38

0.44 (1.05%)

BA

Boeing

$354.92

-0.57 (-0.16%)

MRK

Merck

$62.51

(0.00%)

  • 22

    Jul

  • 23

    Jul

  • 23

    Jul

  • 25

    Jul

  • 25

    Jul

  • 27

    Jul

  • 08

    Aug

  • 15

    Aug

  • 22

    Aug

  • 10

    Sep

  • 10

    Sep

  • 20

    Oct

  • 23

    Oct

  • 28

    Oct

  • 28

    Oct

  • 28

    Jan

  • 16

    Feb

  • 22

    Mar

DDAIF Daimler AG
$0.00

(0.00%)

07/05/18
MZHO
07/05/18
NO CHANGE
MZHO
June Class 8 truck orders rose 'astounding' 133% year-over-year, says Mizuho
June Class 8 truck orders didn't just beat estimates, the actual number "made everyone look silly," Mizuho analyst Kristine Kubacki tells investors in a research note. Class 8 orders surged to 42,200 units in June, up an "astonishing" 133% year-over-year, Kubacki writes. The number handily beat the 30,000 mid-point of her estimate. Publicly traded truck makers and suppliers include Daimler AG (DDAIF), Paccar (PCAR), CNH Industrial (CNHI), Navistar (NAV), Cummins (CMI) and Allison Transmission (ALSN). :theflyo
07/05/18
07/05/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Fiat Chrysler (FCAU) upgraded to Buy from Hold and Daimler AG (DDAIF) upgraded to Hold from Underperform at Jefferies with analyst Philippe Houchois citing valuation. 2. Danone (DANOY) upgraded to Outperform from Sector Perform at RBC Capital with analyst James Jones saying he now has less "punitive" assumptions about the company's sales growth and capital expenditures as its profits have become less reliant on dairy. 3. Hexcel (HXL) upgraded to Buy from Hold at Canaccord with analyst Ken Herbert stating he believes the acceleration in growth expected in 2018 will continue into 2019. 4. Qorvo (QRVO) upgraded to Overweight from Sector Weight at KeyBanc with analyst Michael McConnell citing healthy China smartphone trends, stabilizing Apple (AAPL) iPhone demand, and greater than expected market share gains in China smartphones. 5. Advanced Energy (AEIS) upgraded to Outperform from Market Perform at Raymond James with analyst Pavel Molchanov saying the company's 9% free cash flow yield has turned the shares into an appealing deep value story, despite slowing organic growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/05/18
JEFF
07/05/18
UPGRADE
Target $23
JEFF
Buy
Jefferies upgrades Fiat Chrysler to Buy on valuation
Jefferies analyst Philippe Houchois upgraded Fiat Chrysler (FCAU) to Buy from Hold while lowering his price target for the shares to $23 from $26. The analyst this morning also upgraded Daimler AG (DDAIF) to Hold from Underperform. The analyst cites valuation for both upgrades. The recent selloff in Fiat Chrysler looks "severe" given the likelihood of increasing margins, the 24% free cash flow yield, and the potential for corporate change, Houchois tells investors in a research note.
07/05/18
JEFF
07/05/18
UPGRADE
JEFF
Hold
Daimler AG upgraded to Hold from Underperform at Jefferies
Jefferies analyst Philippe Houchois upgraded Daimler AG to Hold while lowering his price target for the shares to EUR 58 from EUR 60. The analyst believes the shares at current levels are already pricing in concerns about lower margins versus peers, risks to the dividend, and a sub-optimal approach to separating cars and trucks.
FCAU Fiat Chrysler
$19.33

-0.195 (-1.00%)

07/17/18
JEFF
07/17/18
NO CHANGE
Target $25
JEFF
Buy
Santander Consumer, Fiat Chrysler tolling agreement doesn't change much, says Jefferies
Jefferies analyst John Hecht notes that Santander Consumer (SC) and Fiat Chrysler (FCAU) entered a tolling agreement that allows both parties additional time to assess their rights, obligations, claims, etc. while not having to worry about the statute of limitations. The analyst believes the tolling agreement does not change much of what is going on. Nonetheless, Hecht notes that the companies also acknowledged they are working to resolve the matter tied to the captive finance, with the agreement indicating that a resolution on this matter may come in months rather than quarters. He reiterates a Buy rating and $25 price target on Santander Consumer shares.
07/10/18
UBSW
07/10/18
UPGRADE
UBSW
Buy
UBS upgrades Fiat Chrysler to Buy ahead of Q2 results
UBS analyst Patrick Hummel upgraded Fiat Chrysler (FCAU) to Buy from Neutral with a price target of EUR 23. The analyst expects the company's "positive volume/mix impact story" to continue in Q2 even with the ramp of the new RAM 1500 truck unlikely to be completed until Q3. Fiat shares should deliver the best earnings momentum among the European car manufacturers in the coming quarters, Hummel tells investors in a research note.
07/10/18
UBSW
07/10/18
UPGRADE
UBSW
Buy
Fiat Chrysler upgraded to Buy from Neutral at UBS
UBS analyst Patrick Hummel upgraded Fiat Chrysler to Buy.
F Ford
$10.56

-0.115 (-1.08%)

07/20/18
07/20/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. BOFA CUTS YUM CHINA TO UNDERPERFORM: BofA Merrill Lynch analyst Chen Luo downgraded Yum China (YUMC) to Underperform from Neutral and cut its price target to $34 from $44.30. Luo said he expects Yum China to continue to underperform given a likely peak in KFC trends amid China's weakening macro environment, a likely prolonged turnaround at Pizza Hut combined with heavy costs, a slowdown in Chinese consumer consumption, and RMB depreciation. Yum China is down 4.8% in late morning trading. CREDIT SUISSE CUTS FIVE BELOW TO NEUTRAL: Credit Suisse analyst Judah Frommer downgraded Five Below (FIVE) to Neutral from Outperform, telling investors that he is moving to the sidelines as he sees risk/reward balanced at current levels given the stock's material outperformance and back-half comp acceleration that he believes is priced into shares. Frommer keeps his $110 price target and says Five Below remains one of the most differentiated concepts in retail. Five Below is down 4.4% in late morning trading. BAIRD MORE CAUTIOUS ON DRUG SUPPLY CHAIN: Baird analyst Eric Coldwell downgraded Express Scripts (ESRX), AmerisourceBergen (ABC), and McKesson (MCK), all to Neutral from Outperform, citing the heavy political attack in recent weeks against pharmacy benefit managers and members of the drug supply chain. Among them, he said AmerisourceBergen remains his preferred name, but he cannot justify putting new money to work in these names in the current environment. SUNTRUST STARTS VIKING WITH A BUY: SunTrust analyst Edward Nash initiated Viking Therapeutics (VKTX) with a Buy rating and a price target of $14, saying its VK2809 drug for lipid disorders "has the potential to become a promising treatment by addressing multiple metabolic issues" associated with the non-alcoholic steatohepatitis disease, or NASH. Viking is up 8.3% in late morning trading. JPMORGAN SAYS BUY GM, SELL TESLA INTO EARNINGS: JPMorgan analyst Ryan Brinkman forecast lower than consensus Q2 earnings for Ford (F) and higher than consensus earnings for General Motors (GM). The analyst is also concerned about the potential for a "large loss and accompanying large cash outflow" at Tesla (TSLA) in Q2 to "make the bridge" to GAAP profitability and positive cash generation in the second half of the year. Brinkman maintained Overweight ratings on GM and Ford, with a preference for GM shares. He also kept his cautious Underweight rating on Tesla shares, seeing 44% downside to his $180 December 2018 price target.
06/06/18
MSCO
06/06/18
NO CHANGE
Target $16
MSCO
Overweight
Morgan Stanley questions if Ford has a 'business problem or a marketing problem'
Morgan Stanley analyst Adam Jonas estimate that Ford's F-Series pickup truck will produce $42B of revenues in 2018 and produce net income of approximately $6.5B. Excluding Ford Motor, he believes the F-Series franchise would rank #72 on the Fortune 500 list by revenues and that the F-Series ranks "well inside the top 50 companies" in the U.S. in terms of profitability. Given these estimates, Jonas wonders in his note to investors whether Ford has "a business problem or a marketing problem," questioning if the stock market just does "not appreciate the extremely large value of the F-Series business" or if it offsets this large value with "an implied large negative value" of over $10B for the rest of Ford's business. Jonas maintains an Overweight rating and $16 price target on Ford shares.
07/20/18
JPMS
07/20/18
NO CHANGE
JPMS
Overweight
JPMorgan says buy GM, sell Tesla into Q2 earnings reports
JPMorgan analyst Ryan Brinkman forecasts lower than consensus Q2 earnings for Ford (F) and higher than Street earnings for General Motors (GM). Both companies are likely to be impacted by higher commodity costs during the quarter, although the decline in spot prices subsequent to the quarter should limit impact to the full year, Brinkman tells investors in a research note previewing the Q2 earnings for the automakers. The analyst is also concerned about the potential for a "large loss and accompanying large cash outflow" at Tesla in Q2 to "make the bridge" to GAAP profitability and positive cash generation in the second half of the year. Brinkman maintains Overweight ratings on GM and Ford, with a preference for GM shares. He also keeps his cautious Underweight rating on Tesla shares, seeing 44% downside to his $180 December 2018 price target.
07/13/18
GSCO
07/13/18
DOWNGRADE
Target $142
GSCO
Neutral
Visteon downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst David Tamberrino downgraded Visteon (VC) to Neutral from Buy, citing potential near-term risks given its high exposure to Ford (F), high 2019 consensus revenue growth expectations, and risk for its DriveCore AV/ADAS platform. Tamberrino, who thinks 2019 may be a "gap year" for revenue growth, cut his price target on Visteon shares to $142 from $150.
GM General Motors
$39.39

0.08 (0.20%)

06/18/18
NORL
06/18/18
NO CHANGE
Target $15
NORL
Outperform
TeleNav integration at GM a 'strong sign' of coming ramp-up, says Northland
Northland analyst Michael Latimore said he believes TeleNav (TNAV) is now integrated with General Motors' (GM) electronic data interchange system, which he views as "another strong sign" that GM plans to ramp sales of vehicles with TeleNav's system by the end of 2018. Latimore keeps an Outperform rating and $15 price target on TeleNav shares.
07/10/18
RBCM
07/10/18
NO CHANGE
Target $53
RBCM
Outperform
General Motors price target raised to $53 at RBC Capital
RBC Capital analyst Joseph Spak kept his Outperform rating on General Motors (GM) and nudged his price target to $53 from $52, saying the recent $2.25B investment by Softbank (SFTBF) adds validation to the company's GM Cruise robo-taxi offering plans. Aside from the validation, Spak notes that the investment "provides capital to reach scale commercialization, affords GM capital allocation flexibility, and unlocks GM share price value as Cruise around $7 per share."
HMC Honda
$29.18

-0.19 (-0.65%)

06/02/18
GSCO
06/02/18
UPGRADE
GSCO
Buy
Toyota upgraded to Buy from Neutral at Goldman Sach
Goldman Sachs analyst Kota Yuzawa upgraded Toyota Motor (TM) to Buy with an increased price target of 8,500 yen. The carmaker's U.S. shares closed yesterday up $3.36 to $131.31. While sales growth is unlikely amid increasing competition in the U.S. market, management has made it clear they will be focusing strongly on lowering costs, Yuzawa tells investors in a research note. As such, the analyst expects Toyota to establish a "leaner earnings structure" over the next few years and improve its operating structure. Yuzawa this morning also downgraded Honda Motor (HMC) to Neutral from Buy.
06/06/18
MSCO
06/06/18
NO CHANGE
MSCO
Morgan Stanley says Softbank stake in Cruise significant 'far beyond' just GM
Morgan Stanley analyst Adam Jonas said Softbank's (SFTBF) recently announced investment in GM Cruise "carries significance far beyond" General Motors (GM), arguing that the increasingly conspicuous involvement of "outside validators" such as large-cap tech firms and prominent investors can accelerate perception change in the capital markets about "Auto 2.0." He envisions the possible formation of two different companies currently held under one automaker's roof, which he dubs an Auto 2.0 "Yieldco" and an Auto 2.0 "Growthco." Converting car owners into monthly subscribers could open up significant revenue, profit, and value opportunities for traditional automakers, argues Jonas in a note to investors. Other automaking "OEMs" include Ford (F), Daimler (DDAIF), Toyota (TM), Honda (HMC), Fiat Chrysler (FCAU) and BMW Group (BAMXY).
06/02/18
GSCO
06/02/18
DOWNGRADE
GSCO
Neutral
Honda downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Kota Yuzawa downgraded Honda Motor to Neutral with a reduced price target of 3,900 yen. While the company's motorcycle business, which generates around 30% of earnings, remains strong, the sales environment for the auto business has become challenging in the U.S., Yuzawa tells investors in a research note. Further, the analyst points out that Honda's new model cycle is winding down for its three mainstay cars - Civic, CR-V, and Accord.
07/16/18
NOMU
07/16/18
DOWNGRADE
NOMU
Neutral
Honda downgraded to Neutral from Buy at Nomura Instinet
NSANY Nissan
$0.00

(0.00%)

03/13/18
MSCO
03/13/18
NO CHANGE
MSCO
Morgan Stanley compares automakers to Facebook, Apple in 'Auto 2.0' model
Morgan Stanley analyst Adam Jonas noted that auto companies' valuations have compressed to extremely low levels, but he believes that a move from a vehicle ownership model to a transportation subscriber model could expand the revenue opportunities for the potential "tollkeepers" for the monetization of content and data by "nearly an order of magnitude." Looking at U.S. technology leaders Facebook (FB) and Apple (AAPL), which are both valued on their installed base/subscriber models, can "offer valuable clues" regarding the opportunity for General Motors (GM) and other auto OEMs, said Jonas. Viewing the OEMs though the lens of a subscription model, which should be less cyclical and potentially less capital intensive over time than the current auto model, is relevant to analyzing auto stocks, according to Jonas, who adds that it is still too early to call a winner or loser in "Auto 2.0." Other publicly traded legacy automakers include Fiat Chrysler (FCAU), Ford (F), Honda (HMC), Nissan (NSANY), Toyota (TM), Volkswagen (VLKAY) and Daimler (DDAIF).
TM Toyota
$131.87

0.11 (0.08%)

06/01/18
DAIW
06/01/18
UPGRADE
DAIW
Buy
Toyota upgraded to Outperform from Neutral at Daiwa
06/01/18
06/01/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. American Airlines (AAL) upgraded to Outperform from In-Line at Imperial Capital with analyst Michael Derchin saying American is likely to reduce capacity starting in the post-labor day period, which should be well received by investors. 2. T2 Biosystems (TTOO) upgraded to Outperform from Market Perform at Leerink with analyst Puneet Souda saying this week's T2bacteria FDA clearance expands the company's market opportunity "dramatically" from $1.4B to over $3B. 3. Highwoods Properties (HIW) upgraded to Buy from Hold at Stifel with analyst John Guinee saying he believes the macro environment is changing to the positive for REITs. 4. Toyota (TM) upgraded to Outperform from Neutral at Daiwa. 5. RLJ Lodging Trust (RLJ) upgraded to Overweight from Equal Weight at Barclays with analyst Felicia Hendrix saying she views the current valuation as attractive and sees a strong RevPAR outlook for 2019. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
VLKAY Volkswagen
$0.00

(0.00%)

06/15/18
JEFF
06/15/18
NO CHANGE
Target $53
JEFF
Buy
As VW appointment drives Navistar speculation, Jefferies sees eventual buyout
Noting that Navistar (NAV) shares are rising amid broader market weakness today following a Reuters report that Volkswagen (VLKAY) has appointed a new CFO noted to be an M&A expert, Jefferies analyst Stephen Volkmann said he continues to believe Volkswagen will pursue full ownership of Navistar, although he calls the timing of such an event "highly uncertain." He maintains a Buy rating and "Street high" price target of $53 on Navistar shares.
04/25/18
JEFF
04/25/18
UPGRADE
JEFF
Buy
Volkswagen upgraded to Buy from Hold at Jefferies
Jefferies analyst Philippe Houchois upgraded Volkswagen to Buy and raised his price target for the shares to EUR 220 from EUR 180. The analyst likes the recent management changes but says what matters most is the "generational change at Porsche SE," which he views as VW's "most promising agent of change." The analyst is "convinced" that VW-Porsche have what it takes to be the next FCA-Exor.
04/25/18
JEFF
04/25/18
NO CHANGE
Target $53
JEFF
Buy
VW acquisition scenario supports $53 Navistar target, says Jefferies
Recent news flow regarding a separation of Volkswagen's (VLKAY) Truck and Bus business and the potential for full ownership of Navistar (NAV) has driven Navistar shares up 13% relative to the S&P 500 over the past month, Jefferies analyst Stephen Volkmann tells investors in a research note. After examining potential synergies and valuation scenarios for a tie-up, the analyst has increased confidence in his high-on-the-Street $53 price target for Navistar shares.
05/31/18
JEFF
05/31/18
NO CHANGE
JEFF
Buy
Jefferies lists buys on 'wildly overdone' electric truck concerns
The ramp of electric trucks amp may be slower than in passenger cars, and incumbent truck makers are likely to remain key players, Jefferies analyst Stephen Volkmann tells investors in a research note. To a much greater extent than in passenger vehicles, commercial vehicle sales rely on uptime and return on investment, and are driven by brand relationship and dealer support, Volkmann adds. He views the "terminal multiple" concerns for established truck players as "wildly overdone" and recommends buying shares of Paccar (PCAR), Navistar (NAV), Volkswagen (VLKAY) and Volvo (VOLVY).
GOOG Alphabet
$1,184.77

-2.37 (-0.20%)

07/20/18
DBAB
07/20/18
NO CHANGE
Target $1350
DBAB
Buy
Alphabet price target raised to $1,350 from $1,225 at Deutsche Bank
Deutsche Bank analyst Lloyd Walmsley raised his price target for Alphabet (GOOG) to $1,350 and keeps a Buy rating on the shares. While the analyst is bullish on Alphabet shares over the medium and long term, he views the Q2 results setup as "slightly tricky." The analyst expects Google's margins to continue to be under pressure year-over-year. Walmsley sees Alphabet as "well positioned, inexpensive, and a grind-higher type of name with an improving story around slower deleverage and a potential catalyst around Waymo."
07/18/18
BARD
07/18/18
NO CHANGE
Target $1300
BARD
Outperform
EC ruling against Google is 'pro-Amazon,' says Baird
Baird analyst Colin Sebastian believes the European Commission's ruling against Google (GOOGL) is "a bit misguided," but he also thinks it should have a limited direct impact on Google since it ostensibly does not force a change to its search algorithm and seems "relatively straight-forward" to comply with. The "pro-Amazon ruling" has obvious benefits to Amazon (AMZN) and potentially Apple (AAPL), argues Sebastian, as he notes that the EC will require Android users to take another step before they can access an alternative product search engine and forcing Google to support forked-versions of Android could directly benefit Amazon's Fire devices. Despite the direct and/or indirect benefits of this ruling for Apple and Amazon, Sebastian maintains his positive view on Alphabet and keeps an Outperform rating and $1,300 price target on the shares.
07/20/18
PIPR
07/20/18
NO CHANGE
Target $250
PIPR
Overweight
Facebook price target raised to $250 from $210 at Piper Jaffray
Piper Jaffray analyst Michael Olson raised his price target for Facebook (FB) to $250 from $210 after taking over coverage of the shares. The social networking giant closed yesterday down $1.27 to $208.09. Facebook continues to co-dominate the digital advertising world, excluding China, along with Alphabet (GOOG, GOOGL), as advertisers shift budgets from legacy offline channels into high return-on-investment targetable online channels, Olson tells investors in a research note. The analyst sees a "strong long-term revenue growth trajectory" for Facebook as advertising cost per thousand impressions increase in-line with a growing share of total advertising budgets. He notes, however, that the company's new focus on investments in Watch content and safety and security may reduce margin expansion potential in the near term. Olson keeps Piper's Overweight rating on shares of Facebook.
07/18/18
07/18/18
DOWNGRADE

Neutral
Macquarie sees mixed results for U.S. internet large-caps, downgrades Twitter
As previously reported, Macquarie analyst Benjamin Schachter downgraded Twitter (TWTR) to Neutral from Outperform, citing concerns about MAU trends, what he views as a limited set of near-term catalysts and a valuation he believes will likely limit upside from current levels. In his note previewing the upcoming earnings season for U.S. large-cap internet names, Schachter said he expects "somewhat mixed results," identifying Amazon (AMZN), Facebook (FB) and Apple (AAPL) as the stocks on which he is most bullish. He added that he is "increasingly frustrated" with the lack of visibility into the core revenue drivers for Alphabet (GOOGL) and he does not "expect much" from eBay (EBAY) this quarter.
GOOGL Alphabet Class A
$1,198.05

-1.21 (-0.10%)

07/20/18
MKMP
07/20/18
NO CHANGE
Target $255
MKMP
Buy
Facebook expected Q2 expense ramp may be too aggressive, says MKM Partners
MKM Partners analyst Rob Sanderson is keeping his Buy rating and $255 price target on Facebook (FB) ahead of its results next week, saying he expects revenue upside and believes that the anticipated ramp in expenses implied in the consensus for earnings may be too aggressive. The analyst also cites greater visibility on monetization and opportunities in WhatsApp and Messenger justifying a higher multiple, which he sees at a full 3-point discount relative to Google (GOOGL) in spite of Facebook's much higher rate of growth.
07/19/18
RHCO
07/19/18
UPGRADE
Target $27
RHCO
Buy
Lionsgate upgraded to Buy at SunTrust on stronger Starz slate
As reported earlier, SunTrust analyst Matthew Thornton upgraded Lionsgate (LGF.B) to Buy from Hold, citing expectations of a stronger content slate at Starz driving the higher subscriber count while also increasing its distribution, with the addition of Amazon (AMZN) UK/Germany, YouTube (GOOGL) TV USA, Hulu TV USA, and Bell Canada. The analyst also anticipates higher subs count amid abating Starz MVPD headwinds from international expansion and secular growth in OTT. Thornton lowers his price target to $27 from $31, but notes that his target multiple assumption and OIBDA forecast for FY19 and FY20 are largely unchanged.
PFE Pfizer
$37.33

-0.03 (-0.08%)

07/17/18
CANT
07/17/18
NO CHANGE
CANT
Overweight
Aclaris offers best risk/reward of hair loss players, says Cantor Fitzgerald
The potential for JAK inhibitors to treat alopecia areata may be underappreciated by investors because the Street does not appear to be ascribing enough value to the opportunity, Cantor Fitzgerald analyst Louise Chen tells investors in a research note. Of the three companies she covers developing JAKs for hair loss, Aclaris Therapeutics (ACRS), Eli Lilly (LLY) and Pfizer (PFE), the analyst believes Aclaris offers the best risk/reward and greatest upside potential. The company has a market cap below $700M and two potential "shots on goal" for alopecia areata, Chen writes. She estimates combined peak sales of $1B-plus for both opportunities and keeps an Overweight rating on Aclaris. The physicians the analyst spoke to believe the company's JAKs for hair loss will work.
07/18/18
PIPR
07/18/18
NO CHANGE
Target $450
PIPR
Overweight
Piper maintains Overweight on Regeneron on tanezumab news
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Regeneron Pharmaceuticals (REGN) on news that tanezumab, Pfizer (PFE) and Eli Lilly's (LLY) anti-NGF antibody that is a competitor to Regeneron's fasinumab, successfully completed the first of several Phase 3 trials. Fasinumab remains an unmodeled opportunity, but the read-through from tanezumab is positive and the market for an effective, non-opioid chronic pain treatment is "massive," Raymond tells investors in a research note. The analyst points out that Regeneron and Teva (TEVA) still expect to report Phase 3 data starting later this year. Raymond keeps an Overweight rating on Regeneron with a $450 price target.
07/17/18
HCWC
07/17/18
NO CHANGE
Target $42
HCWC
Buy
uniQure pullback on Pfizer study unwarranted, says H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay notes that shares of uniQure (QURE) dropped 11% yesterday after Pfizer (PFE) initiated an "open-label, non-investigational product, multi-center, lead-in study to evaluate at least 6 months of prospective efficacy and selected safety data of factor IX prophylaxis replacement therapy in moderate to severe adult Hemophilia B subjects who are negative for neutralizing antibodies to adeno-associated virus vector-spark100". This has been potentially misconstrued as the initiation of the Phase 3 study, suggesting competitive threats for uniQure earlier than anticipated, Chattopadhyay tells investors in a research note. However, this is not to be mistaken as a gene therapy Phase 3 program, as there is no gene therapy treatment cohort, the analyst adds. Further, Chattopadhyay points out that Pfizer's observation study is expected to be completed during November of 2020, which he believes puts uniQure at least a year, if not more, ahead. In addition, the analyst continues to believe that Pfizer is likely to encounter intellectual property headwinds given uniQure's patent asset protecting both the mPadua gene cassette and its method of use to treat hemoglobinopathies. He views the selloff yesterday in shares of uniQure as unwarranted and keeps a Buy rating on the name with a $42 price target.
07/18/18
WELS
07/18/18
NO CHANGE
WELS
Novartis report has negative read through for Teva, Mylan, says Wells Fargo
Wells Fargo analyst David Maris noted that Novartis (NVS) lowered its 2018 guidance for Sandoz along with its Q2 report and reportedly told Bloomberg that it would consider selling the generic drug unit. He sees a negative read through for companies with large U.S. commodity generic exposure, such as Teva (TEVA) and Mylan (MYL), from Novartis' report, Maris tells investors. He also noted that Novartis said it will not increase prices on its drugs in the U.S. for the rest of 2018, as Pfizer (PFE) recently has also said, calling this "a wise approach and correct read of the increasing intensity of the scrutiny around rising healthcare costs." Maris continues to expect the " chilling effect" on price increases to spread through the industry. Lastly, the analyst pointed out that the Amgen-partnered (AMGN) launch of Aimovig is off to a strong start, which he believes bodes well for Teva's fremanezumab and Eli Lilly's (LLY) galcanezumab.
NVS Novartis
$82.28

1.47 (1.82%)

07/19/18
LEHM
07/19/18
UPGRADE
LEHM
Equal Weight
Novartis upgraded to Equal Weight from Underweight at Barclays
07/19/18
WELS
07/19/18
NO CHANGE
Target $240
WELS
Outperform
Allergan wet AMD data exceed 'unofficial benchmark,' says Wells Fargo
The released efficacy data from Allergan's (AGN) two Phase III trials of its anti-VEGF treatment abicipar in wet age-related macular degeneration looks to have exceeded the "unofficial benchmark set by potential extended-duration competitors," Novartis' (NVS) brolucizumab and Regeneron's (REGN) Eylea, Wells Fargo analyst David Maris tells investors in a research note. The analyst forecasts $125M in sales for abicipar in its first year on the market in 2020 and estimates it will grow to $500M in 2022. Maris keeps an Outperform rating on Allergan with a $240 price target.
07/16/18
MSCO
07/16/18
INITIATION
Target $37
MSCO
Overweight
AvroBio initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst David Lebowitz initiated AvroBio (AVRO) with an Overweight rating and $37 price target, noting that its a unique gene therapy company that has human clinical data for one of its programs at the time of its initial public offering. He points to Novartis' (NVS) recent acquisition of AveXis for $8.7B, or an 88% premium, as an illustration of the substantial interest in and valuation premium put into many names in the gene therapy space.
RHHBY Roche
$0.00

(0.00%)

07/11/18
ADAM
07/11/18
NO CHANGE
Target $140
ADAM
Buy
Celgene's Buy rating backed at Canaccord following Phase 3 Impassion130 results
Canaccord analyst John Newman maintained a Buy rating and $140 price target on Celgene (CELG) after the company said that the Phase 3 Impassion130 study showed progression-free survival, or PFS, improvement for 1L metastatic or unresectable triple negative breast cancer with Abraxane plus Tecentriq (RHHBY) , which opens the door to Tencentriq in this indication. In a research note to investors, Newman says he expects continued upside from pipeline advances and diversification based on in-licensing, M&A and organic R&D and that, as there are currently no alternatives to chemotherapy, the combination of Abraxane plus Tecentriq should see widespread use if approved. He views the advances in TNBC "very positively" given the high unmet need for viable therapy.
06/28/18
WELS
06/28/18
NO CHANGE
WELS
Wells says Amazon deal, Walgreens results have negative read for drug pricing
After Amazon (AMZN) agreed to acquire online pharmacy PillPack, reportedly for $1B, Wells Fargo analyst David Maris noted that he has long stated that Amazon would enter the pharmacy business and warned about the risk to drug pricing in such a scenario. Maris also noted that Walgreens (WBA) reported its U.S. retail pharmacy comparable store sales fell 1.2% in Q3, adding that retailers tend to push drugmakers on price when they feel pressure and the read-through from its report may be negative for drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/11/18
WELS
07/11/18
NO CHANGE
WELS
Drug stocks may not react favorably to Pfizer price rollback, Trump tweets, says Wells Fargo
Wells Fargo analyst David Maris notes that there was widespread media coverage of drug price increases taken recently by several large cap drug companies, with President Trump criticizing Pfizer (PFE) for taking these price increases. On Tuesday, Pfizer confirmed it was rolling back its July drug price increases following a conversation with President Trump, he adds. Maris believes that drug stocks will not react favorably to this news, given the chilling effect this will likely have on others looking to take price increases. Nonetheless, the analyst points out that the price increases taken in July are only a small number of increases taken over the past year or several years, so the impact of the rollback to the healthcare system is insignificant in the big picture. Other publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
07/11/18
PIPR
07/11/18
NO CHANGE
Target $365
PIPR
Overweight
Biogen price target raised to $365 from $353 at Piper Jaffray
Piper Jaffray analyst Christopher Raymond raised his price target for Biogen (BIIB) to $365 saying a survey of 101 neurologists gives him increased confidence in the staying power of the company's multiple sclerosis franchise. Tecfidera market share "edged up slightly" during the quarter, and the survey shows signs of Roche's (RHHBY) Ocrevus "hitting a bit of a wall," Raymond tells investors in a research note. Further, the analyst continues to hear feedback that Celgene's (CELG) ozanimod "will be minimally differentiated." Despite increased signs of payer activism in the space, Biogen's MS franchise is well positioned for the near-to-intermediate term, Raymond contends. He raised his estimates for Tecfidera and keeps an Overweight rating on Biogen.
SNY Sanofi
$42.38

0.44 (1.05%)

07/02/18
PIPR
07/02/18
NO CHANGE
Target $450
PIPR
Overweight
Regeneron has 'substantial' opportunity for Q2 upside, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says that with Dupixent script trends indicated up almost 30% quarter-over-quarter, Regeneron's (REGN) opportunity for Q2 upside is "substantial." Further, Regeneron and Sanofi (SNY) over the weekend raised the list price by 3% for the drug's first ever price increase, Raymond tells investors in a research note. He thinks Dupixent remains well positioned to outperform expectations "this quarter and beyond." The analyst maintains an Overweight rating on Regeneron with a $450 price target.
07/10/18
07/10/18
DOWNGRADE
Target $1

Neutral
Regulus downgraded to Neutral at Wedbush
As previously reported, Wedbush analyst Liana Moussato downgraded Regulus (RGLS) to Neutral from Outperform after he extended developmental timelines due to partnership restructuring with Sanofi (SNY) pausing clinical enrollment for RG-012 and unexpected mouse toxicity observations delaying clinical progress for RGLS4326. The analyst also lowered his price target on Regulus shares to $1 from $3.
07/19/18
BMOC
07/19/18
NO CHANGE
Target $80
BMOC
Market Perform
Eli Lilly to have a 'good Q2' on beats from launch franchises, says BMO Capital
BMO Capital analyst Alex Arfaei raised his price target on Eli Lilly to $80 from $78 ahead of its Q2 earnings, saying the company will have a "good" quarter on "beats from its launch franchises Trulicity, Jardiance, and Basaglar". The analyst also keeps his Market Perform rating, adding that while the the pipeline potential of its Galcanezumab and Tanezumab drugs is promising, he believes investors are underappreciating the headwinds around its diabetes program. He see higher risks of an increased biosimilar erosion for Humalog from Sanofi's (SNY) Admelog, and Trulicity competitive pressure from Novo's (NVO) Ozempic in 2019.
BA Boeing
$354.92

-0.57 (-0.16%)

07/06/18
WBLR
07/06/18
NO CHANGE
WBLR
Market Perform
Embraer shares likely to remain in trading range, says William Blair
Embraer's (ERJ) shares are likely to remain in a trading range in the low-mid $20s pending completion of several critical steps for the commercial aviation joint venture with Boeing (BA) over the next several quarters, William Blair analyst Nicholas Heymann tells investors in a research note. The analyst, however, views the agreement as a strategic long-term positive for Embraer. After 20% projected taxes, Embraer will likely have about $3.05B to reduce its remaining debt, fund additional upgrades for its KC-390 light military transport and executive aviation, and provide a special dividend and/or share repurchase for shareholders, Heymann writes. He keeps a Market Perform rating on the shares.
07/11/18
BARD
07/11/18
NO CHANGE
Target $450
BARD
Outperform
Boeing on path to over $400, reflecting 'robust' FCF generation, says Baird
Baird analyst Peter Arment said he expects Boeing to report a "solid" second quarter on July 25, reflecting "favorable" aircraft deliveries. In a research note to investors, Arment says he is "comfortable" with both short- and long-term investors being long into the print and continues to see the stock on a path to over $400, reflecting strong free cash flow generation. He expects management will reiterate its delivery outlook for 2018 and back its 737-MAX delivery target despite recent headlines on suply chain pressures. Arment has an Outperform rating and $450 price target on Boeing shares.
07/11/18
07/11/18
UPGRADE
Target $408

Outperform
TransDigm upgraded to Outperform on reduced risks at Cowen
As previously reported, Cowen upgraded TransDigm (TDG) to Outperform from Market Perform with a $408 price target telling investors fundamental threats to TransDigm's aftermarket/M&A playbook are abating. Analyst Gautam Khanna said contract talks between TransDigm and Boeing (BA) are close to being agreed upon with no major threats to TransDigm, and concerns regarding deal economics appear to be misplaced. Further, the Department of Defense procurement rule as of July 1 may actually provide TransDigm with more pricing power versus the old policy, Khanna wrote in a note to investors. The analyst adds, the Department of Defense inquiry is also nearing completion with any fines likely to be minimal, end markets are improving, and the company has $2.3B available for M&A or dividends.
07/10/18
BARD
07/10/18
NO CHANGE
Target $450
BARD
Outperform
Baird says Boeing Q2 deliveries top expectation
Boeing announced Q2 final deliveries of 194 commercial aircraft, which Baird analyst Peter Arment noted was seven more than the 187 planes that his checks had indicated. Boeing also finished the quarter with 239 net orders and a "strong" book-to-bill of 1.23x, said Arment, expects a solid Q2 earnings report from Boeing on July 25. He maintains an Outperform rating and $450 price target on Boeing shares.
MRK Merck
$62.51

(0.00%)

06/13/18
MSCO
06/13/18
NO CHANGE
MSCO
HHS 'smoke signals' worth noting for drugmakers, says Morgan Stanley
After HHS Secretary Alex Azar spoke at a two-hour Senate hearing, Morgan Stanley analyst David Risinger noted that Azar suggested that U.S. drug pricing needs to move to a system without rebates and said payments from drugmakers to PBMs should be eliminated. In listing four HHS actions that could hurt manufacturers, Risinger pointed out that Azar said he is interested in removing 100% cap on Medicaid rebates; he would like to adjust the Part D protected drug classes so that plans can extract rebates from manufacturers; HHS wants to require manufacturers to disclose drug list prices in TV ads; and HHS is focused on transitioning Part B to lower-priced private sector management. In summary, the analyst said that for drugmakers there was "no fire, but smoke signals worth noting." Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
06/14/18
MSCO
06/14/18
NO CHANGE
Target $68
MSCO
Overweight
Merck Q2 estimates lowered below consensus at Morgan Stanley
Morgan Stanley analyst David Risinger cut his Q2 revenue estimate for Merck by 1% to $10.1B, which he notes is below the consensus view of $10.3B, and lowered his Q2 EPS estimate by 6% to 97c. This is below the consensus view of $1.03, which he argues "needs to come down." The two key drivers were lowering his estimates for Keytruda in the U.S. due to a more gradual ramp in first-line lung cancer patients and the negative impact of hedging, which he sees being similar to, but less pronounced, than in Q1. He lowered his full-year EPS view by only 1%, however, which puts it 2% below consensus. Risinger keeps an Overweight rating and $68 price target on Merck shares.

TODAY'S FREE FLY STORIES

JD

JD.com

$23.04

-1.18 (-4.87%)

, SPB

Spectrum Brands

$59.36

0.87 (1.49%)

20:25
11/18/18
11/18
20:25
11/18/18
20:25
Earnings
Notable companies reporting before Monday's open »

Notable companies…

JD

JD.com

$23.04

-1.18 (-4.87%)

SPB

Spectrum Brands

$59.36

0.87 (1.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

AAPL

Apple

$193.42

2 (1.04%)

, PCG

PG&E

$24.39

6.62 (37.25%)

19:29
11/18/18
11/18
19:29
11/18/18
19:29
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

AAPL

Apple

$193.42

2 (1.04%)

PCG

PG&E

$24.39

6.62 (37.25%)

CBS

CBS

$57.49

0.23 (0.40%)

VIA

Viacom

$37.05

0.96 (2.66%)

VIAB

Viacom

$33.00

1.13 (3.55%)

AMZN

Amazon.com

$1,593.59

-26.41 (-1.63%)

KSS

Kohl's

$72.48

-0.7 (-0.96%)

TGT

Target

$79.67

-1.09 (-1.35%)

HD

Home Depot

$177.11

-0.25 (-0.14%)

TIF

Tiffany

$106.48

0.52 (0.49%)

BBY

Best Buy

$66.41

-1.34 (-1.98%)

TJX

TJX

$51.47

-0.98 (-1.87%)

JCP

J.C. Penney

$1.29

-0.08 (-5.84%)

LB

L Brands

$35.28

-0.41 (-1.15%)

T

AT&T

$30.30

0.18 (0.60%)

BP

BP

$40.85

-0.3 (-0.73%)

CVX

Chevron

$119.14

2.18 (1.86%)

XOM

Exxon Mobil

$78.99

0.81 (1.04%)

RDS.A

Royal Dutch Shell

$62.02

0.34 (0.55%)

RDS.B

Royal Dutch Shell

$63.97

0.19 (0.30%)

APC

Anadarko

$56.39

0.9 (1.62%)

EOG

EOG Resources

$105.21

3.57 (3.51%)

OXY

Occidental Petroleum

$73.32

0.71 (0.98%)

COG

Cabot Oil & Gas

$25.73

0.09 (0.35%)

EQT

EQT Corporation

$16.62

-0.55 (-3.20%)

HAL

Halliburton

$32.46

0.02 (0.06%)

SLB

Schlumberger

$48.24

0.17 (0.35%)

AMGN

Amgen

$194.23

1.83 (0.95%)

THS

TreeHouse

$51.92

0.72 (1.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 26

    Nov

  • 27

    Nov

  • 28

    Nov

  • 01

    Dec

  • 02

    Dec

  • 03

    Dec

  • 03

    Dec

  • 03

    Dec

  • 04

    Dec

  • 04

    Dec

  • 05

    Dec

  • 18

    Jan

  • 22

    Jan

  • 03

    Mar

ZAYO

Zayo Group

$23.70

1.495 (6.73%)

, BX

Blackstone

$32.48

-0.02 (-0.06%)

18:50
11/18/18
11/18
18:50
11/18/18
18:50
Periodicals
Zayo said to get interest from Blackstone-Stonepeak Group, Bloomberg reports »

Zayo (ZAYO) has attracted…

ZAYO

Zayo Group

$23.70

1.495 (6.73%)

BX

Blackstone

$32.48

-0.02 (-0.06%)

KKR

KKR

$21.83

-0.46 (-2.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

  • 03

    Dec

PCG

PG&E

$24.39

6.62 (37.25%)

18:08
11/18/18
11/18
18:08
11/18/18
18:08
Periodicals
PG&E reports another outage on morning when California started, Reuters says »

PG&E, facing investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KL

Kirkland Lake Gold

$18.97

0.28 (1.50%)

18:04
11/18/18
11/18
18:04
11/18/18
18:04
Hot Stocks
Kirkland Lake Gold appoints David Soares as CFO, Eric Kallio as senior VP »

Kirkland Lake Gold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXPD

Expeditors

$73.67

0.14 (0.19%)

17:19
11/18/18
11/18
17:19
11/18/18
17:19
Conference/Events
Expeditors management to meet with Wolfe Research »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

CBS

CBS

$57.49

0.23 (0.40%)

, VIAB

Viacom

$33.00

1.13 (3.55%)

16:54
11/18/18
11/18
16:54
11/18/18
16:54
Periodicals
CBS, Viacom merger could be a few months away, NY Post reports »

After CBS (CBS) CEO Les…

CBS

CBS

$57.49

0.23 (0.40%)

VIAB

Viacom

$33.00

1.13 (3.55%)

VIA

Viacom

$37.05

0.96 (2.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 04

    Dec

AIMT

Aimmune

$29.61

0.05 (0.17%)

16:51
11/18/18
11/18
16:51
11/18/18
16:51
Hot Stocks
PALISADE trial of Aimmune's AR101 published in New England Journal of Medicine »

Aimmune Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 12

    Dec

T

AT&T

$30.30

0.18 (0.60%)

, CMCSA

Comcast

$38.60

0.11 (0.29%)

16:31
11/18/18
11/18
16:31
11/18/18
16:31
Hot Stocks
Box Office Battle: 'Fantastic Beasts 2' wins weekend with $62M »

AT&T (T) subsidiary…

T

AT&T

$30.30

0.18 (0.60%)

CMCSA

Comcast

$38.60

0.11 (0.29%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$50.80

-0.81 (-1.57%)

FOX

21st Century Fox

$47.73

-0.1 (-0.21%)

FOXA

21st Century Fox

$48.18

-0.11 (-0.23%)

LGF.A

Lionsgate

$20.88

0.365 (1.78%)

DIS

Disney

$116.20

-0.9 (-0.77%)

VIAB

Viacom

$33.00

1.13 (3.55%)

VIA

Viacom

$37.05

0.96 (2.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 04

    Dec

VLKAY

Volkswagen

$0.00

(0.00%)

, GOOG

Alphabet

$1,062.01

-2.73 (-0.26%)

15:45
11/18/18
11/18
15:45
11/18/18
15:45
Periodicals
Volkswagen CEO says Waymo has 1/2-year head start, Reuters reports »

Volkwagen (VLKAY) is up…

VLKAY

Volkswagen

$0.00

(0.00%)

GOOG

Alphabet

$1,062.01

-2.73 (-0.26%)

GOOGL

Alphabet Class A

$1,069.13

-2.09 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 03

    Mar

T

AT&T

$30.30

0.18 (0.60%)

, FOX

21st Century Fox

$47.73

-0.1 (-0.21%)

15:21
11/18/18
11/18
15:21
11/18/18
15:21
Hot Stocks
AT&T, Fox Networks renew multi-year deal across distribution platforms »

AT&T (T) and Fox…

T

AT&T

$30.30

0.18 (0.60%)

FOX

21st Century Fox

$47.73

-0.1 (-0.21%)

FOXA

21st Century Fox

$48.18

-0.11 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 04

    Dec

AAPL

Apple

$193.42

2 (1.04%)

13:35
11/18/18
11/18
13:35
11/18/18
13:35
Periodicals
Apple CEO views new regulations as 'inevitable,' Axios reports »

Apple CEO Tim Cook says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSRGY

Nestle

$0.00

(0.00%)

, RIO

Rio Tinto

$50.94

0.89 (1.78%)

13:05
11/18/18
11/18
13:05
11/18/18
13:05
Periodicals
Nespresso, Rio Tinto joining forces to make coffee pods greener, Reuters says »

Nespresso, part of food…

NSRGY

Nestle

$0.00

(0.00%)

RIO

Rio Tinto

$50.94

0.89 (1.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNOA

Sonoma Pharmaceuticals

$1.11

-0.095 (-7.92%)

12:54
11/18/18
11/18
12:54
11/18/18
12:54
Hot Stocks
Sonoma Pharmaceuticals announces pricing of public offering of units »

Sonoma Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

  • 04

    Dec

NVS

Novartis

$87.74

0.52 (0.60%)

, DBVT

DBV Technologies

$16.70

0.31 (1.89%)

04:55
11/18/18
11/18
04:55
11/18/18
04:55
Conference/Events
American College of Allergy, Asthma & Immunology to hold a meeting »

2018 ACAAI Meeting will…

NVS

Novartis

$87.74

0.52 (0.60%)

DBVT

DBV Technologies

$16.70

0.31 (1.89%)

REGN

Regeneron

$345.10

3.56 (1.04%)

SHPG

Shire

$175.59

-3.39 (-1.89%)

TEVA

Teva

$22.25

-0.37 (-1.64%)

SNY

Sanofi

$45.11

0.56 (1.26%)

GSK

GlaxoSmithKline

$40.35

-0.06 (-0.15%)

AZN

AstraZeneca

$40.67

-0.685 (-1.66%)

CHD

Church & Dwight

$65.42

-0.39 (-0.59%)

BSX

Boston Scientific

$37.22

0.75 (2.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 30

    Nov

  • 02

    Dec

  • 03

    Dec

  • 21

    Dec

  • 28

    Jan

  • 11

    Mar

  • 22

    Mar

  • 28

    Apr

  • 13

    May

PDVW

pdvWireless

$39.84

0.06 (0.15%)

16:30
11/17/18
11/17
16:30
11/17/18
16:30
Conference/Events
pdvWireless management to meet with Morgan Stanley »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBS

CBS

$57.49

0.23 (0.40%)

16:28
11/17/18
11/17
16:28
11/17/18
16:28
Conference/Events
CBS management to meet with Morgan Stanley »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

THS

TreeHouse

$51.92

0.72 (1.41%)

, CAG

Conagra Brands

$33.09

0.66 (2.04%)

12:54
11/17/18
11/17
12:54
11/17/18
12:54
Periodicals
Treehouse Foods stock may have room to gain, Barron's says »

Treehouse Foods (THS)…

THS

TreeHouse

$51.92

0.72 (1.41%)

CAG

Conagra Brands

$33.09

0.66 (2.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$194.23

1.83 (0.95%)

12:51
11/17/18
11/17
12:51
11/17/18
12:51
Periodicals
Amgen may be 'a remedy' for tougher times, Barron's says »

Amgen may be a stock that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 01

    Dec

  • 02

    Dec

  • 03

    Dec

  • 03

    Dec

AAPL

Apple

$193.42

2 (1.04%)

, LITE

Lumentum

$41.50

0.46 (1.12%)

12:47
11/17/18
11/17
12:47
11/17/18
12:47
Periodicals
Apple stock could continue to slide, Barron's says »

Apple's (AAPL) stock…

AAPL

Apple

$193.42

2 (1.04%)

LITE

Lumentum

$41.50

0.46 (1.12%)

QRVO

Qorvo

$66.32

1.18 (1.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APC

Anadarko

$56.39

0.9 (1.62%)

, RDS.B

Royal Dutch Shell

$63.97

0.19 (0.30%)

12:41
11/17/18
11/17
12:41
11/17/18
12:41
Periodicals
Investors may find bargains among oil, natural gas stocks, Barron's says »

Investors have been…

APC

Anadarko

$56.39

0.9 (1.62%)

RDS.B

Royal Dutch Shell

$63.97

0.19 (0.30%)

RDS.A

Royal Dutch Shell

$62.02

0.34 (0.55%)

XOM

Exxon Mobil

$78.99

0.81 (1.04%)

CVX

Chevron

$119.14

2.18 (1.86%)

BP

BP

$40.85

-0.3 (-0.73%)

EOG

EOG Resources

$105.21

3.57 (3.51%)

OXY

Occidental Petroleum

$73.32

0.71 (0.98%)

COG

Cabot Oil & Gas

$25.73

0.09 (0.35%)

EQT

EQT Corporation

$16.62

-0.55 (-3.20%)

HAL

Halliburton

$32.46

0.02 (0.06%)

SLB

Schlumberger

$48.24

0.17 (0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 18

    Jan

  • 22

    Jan

LB

L Brands

$35.28

-0.41 (-1.15%)

, JCP

J.C. Penney

$1.29

-0.08 (-5.84%)

12:34
11/17/18
11/17
12:34
11/17/18
12:34
Periodicals
Kohl's, Target set to thrive this holiday season, Barron's says »

Store chains have been…

LB

L Brands

$35.28

-0.41 (-1.15%)

JCP

J.C. Penney

$1.29

-0.08 (-5.84%)

TJX

TJX

$51.47

-0.98 (-1.87%)

BBY

Best Buy

$66.41

-1.34 (-1.98%)

TIF

Tiffany

$106.48

0.52 (0.49%)

HD

Home Depot

$177.11

-0.25 (-0.14%)

TGT

Target

$79.67

-1.09 (-1.35%)

KSS

Kohl's

$72.48

-0.7 (-0.96%)

AMZN

Amazon.com

$1,593.59

-26.41 (-1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 28

    Nov

  • 04

    Dec

  • 05

    Dec

  • 03

    Mar

T

AT&T

$30.30

0.18 (0.60%)

, FOX

21st Century Fox

$47.73

-0.1 (-0.21%)

09:18
11/17/18
11/17
09:18
11/17/18
09:18
OnTheFly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

T

AT&T

$30.30

0.18 (0.60%)

FOX

21st Century Fox

$47.73

-0.1 (-0.21%)

FOXA

21st Century Fox

$48.18

-0.11 (-0.23%)

AMZN

Amazon.com

$1,593.59

-26.41 (-1.63%)

CMCSA

Comcast

$38.60

0.11 (0.29%)

CMCSK

Comcast

$0.00

(0.00%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$16.46

-0.12 (-0.72%)

F

Ford

$9.05

-0.26 (-2.79%)

GM

General Motors

$35.76

0.21 (0.59%)

HMC

Honda

$28.21

0.01 (0.04%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$116.87

-0.02 (-0.02%)

VLKAY

Volkswagen

$0.00

(0.00%)

NYT

New York Times

$26.30

-0.2 (-0.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 03

    Dec

  • 04

    Dec

  • 13

    Dec

  • 23

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

NVS

Novartis

$87.74

0.52 (0.60%)

, DBVT

DBV Technologies

$16.70

0.31 (1.89%)

04:55
11/17/18
11/17
04:55
11/17/18
04:55
Conference/Events
American College of Allergy, Asthma & Immunology to hold a meeting »

2018 ACAAI Meeting will…

NVS

Novartis

$87.74

0.52 (0.60%)

DBVT

DBV Technologies

$16.70

0.31 (1.89%)

REGN

Regeneron

$345.10

3.56 (1.04%)

SHPG

Shire

$175.59

-3.39 (-1.89%)

TEVA

Teva

$22.25

-0.37 (-1.64%)

SNY

Sanofi

$45.11

0.56 (1.26%)

GSK

GlaxoSmithKline

$40.35

-0.06 (-0.15%)

AZN

AstraZeneca

$40.67

-0.685 (-1.66%)

CHD

Church & Dwight

$65.42

-0.39 (-0.59%)

BSX

Boston Scientific

$37.22

0.75 (2.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 30

    Nov

  • 02

    Dec

  • 03

    Dec

  • 21

    Dec

  • 28

    Jan

  • 11

    Mar

  • 22

    Mar

  • 28

    Apr

  • 13

    May

MSI

Motorola Solutions

$129.97

0.72 (0.56%)

18:48
11/16/18
11/16
18:48
11/16/18
18:48
Hot Stocks
Motorola Solutions: ITC confirms Hytera products infringe Motorola patents »

Motorola Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 18

    Dec

  • 19

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.